Astrazeneca (AZN) Long-Term Investments (2009 - 2026)

Astrazeneca has reported Long-Term Investments for 18 years, with the latest figure at $297.0 million in Q2 2026.

• On a quarterly basis, Long-Term Investments rose 7.61% year-over-year to $297.0 million in Q2 2026; TTM through Jun 2026 was $297.0 million, a 7.61% increase from a year earlier, with the FY2025 full-year figure at $302.0 million, up 12.69% from the prior year.
• Long-Term Investments was $297.0 million for Q2 2026 at Astrazeneca, down from $306.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $306.0 million in Q1 2026, with the low at $53.0 million in Q3 2022.
• Average Long-Term Investments over 5 years is $183.6 million, with a median of $205.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Long-Term Investments retreated 28.41% in 2022, then soared 367.74% in 2024.
• Over 5 years, Long-Term Investments stood at $76.0 million in 2022, then surged by 93.42% to $147.0 million in 2023, then soared by 82.31% to $268.0 million in 2024, then rose by 12.69% to $302.0 million in 2025, then dropped by 1.66% to $297.0 million in 2026.
• The last three Long-Term Investments figures came in at $297.0 million (Q2 2026), $306.0 million (Q1 2026), and $302.0 million (Q4 2025), per Business Quant data.